zepbound a glp 1 - HEALTHIES
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its blockbuster GLP-1 therapies, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. In a study, people with gene variants in two genes lost slightly more weight on GLP-1 drugs, but threw up more on Zepbound. Newser on MSN: Taking GLP-1 drugs and feeling 'meh'?
Understanding the Context
You're not alone For some people on blockbuster weight-loss drugs, the number on the scale isn't the only thing dropping—in some cases, their sense of joy is, too. Patients on GLP-1 medications like Ozempic, Wegovy, ... Zacks Investment Research on MSN: How will Mounjaro and Zepbound sales aid LLY's upcoming Q1 results? STAT: Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't actually necessary to achieve effective weight loss.
Image Gallery
Key Insights
Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target